Fig. 1.

Incidences of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. Kaplan–Meier curves of cumulative incidences of MRONJ (a) and the incidences of MRONJ (b) in patients of the ZA alone (n = 350), denosumab alone (n = 402), and ZA-to-denosumab (n = 43) groups are shown. In the ZA-to-denosumab group, patients received a median (IQR) of 8 (2–17) ZA infusions before the first dose of denosumab. *Statistical significance was considered at a p value < 0.0167 for the Chi-square test (the criteria for significance were adjusted using Bonferroni correction). IQR interquartile range, MRONJ medication-related osteonecrosis of the jaw, ZA zoledronic acid